)
Waters (WAT) investor relations material
Waters Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $1.767B; organic revenue was $871M, up 9% reported and 10% in constant currency, while adjusted EPS rose 21% to $4.10.
Total revenue increased 121% year over year, reflecting the February acquisition of Biosciences & Diagnostic Solutions; legacy revenue grew 9% on broad-based gains.
Strong consumables demand, instrument replacement and acquired-business performance supported a $43M increase to the FY26 reported revenue guidance midpoint.
Financial highlights
Adjusted gross margin was 55.8%, adjusted operating margin 30.1%, and adjusted EPS $4.10; GAAP diluted EPS was $0.82.
Q3 GAAP net income was $81M versus $149M; nine-month net loss was $127M versus net income of $417M, reflecting acquisition accounting and related costs.
Adjusted free cash flow was $68M; it included ~$81M of integration, restructuring and SAP costs and $240M of timing items, primarily higher receivables and SAP migration.
Q3 product revenue rose 167% to $1.334B and service revenue rose 44% to $433M; nine-month revenue increased 110% to $4.678B.
Revenue by region was $749M in the Americas, $523M in Europe and $495M in Asia.
Outlook and guidance
FY26 organic constant-currency growth guidance rose 140 bps at midpoint to 9.1%–9.7%; reported revenue guidance increased $43M at midpoint to $6.479B–$6.497B.
FY26 adjusted EPS guidance increased to $14.60–$14.70; adjusted EBIT margin is expected at 28.2%, with a 15.4% tax rate and $196M net interest expense.
Q4 guidance: organic constant-currency growth of 7%–9%, reported revenue of $1.801B–$1.819B and adjusted EPS of $4.58–$4.68; four fewer selling days are assumed.
Q4 guidance assumes double-digit days-adjusted growth in organic and acquired businesses; midpoint implies a 14% sequential organic revenue step-up.
2027 preliminary framework: mid-single-digit-plus combined organic growth, 29.2% adjusted operating margin and low-teens adjusted EPS growth; estimates are not guidance.
- Broad recovery and new-product momentum drove Q4 growth and supported positive 2011 guidance.WAT
Q4 2010 - Core demand lifted Q3 revenue 9% constant currency as FX constrained reported growth.WAT
Q3 2015 - Pharma delays and India weakness slowed Q1; FY outlook still targets 2%-4% reported growth.WAT
Q1 2012 - Q2 growth outpaced expectations, with AI, innovation, and integration driving strong future outlook.WAT
U.S. All Stars Conference - Momentum from innovation, localization, and integration supports high single-digit growth outlook.WAT
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue doubled on BDS acquisition, but acquisition costs led to operating losses.WAT
Q2 2026 - Growth is fueled by innovation, premium pricing, and expanding global regulatory drivers.WAT
Leerink’s Global Healthcare Conference 2025 - Double-digit growth, innovation, and integration drive strong performance and future momentum.WAT
Jefferies Global Healthcare Conference 2026 - High single-digit growth and margin expansion targeted, fueled by innovation and high-growth adjacencies.WAT
Investor Day 2025
)
)
)
)
)
)
)
)